Skip to Content

Join the 'Ovarian Cancer' group to help and get support from people like you.

Ovarian Cancer News

Related terms: Cancer, Ovarian, Cancer, Ovaries

High Blood Pressure: A Silver Lining for Ovarian Cancer Patients?

Posted 19 Apr 2017 by Drugs.com

TUESDAY, April 18, 2017 – A woman's prognosis after an ovarian cancer diagnosis may be affected by a number of unexpected factors, new research suggests. The study found that diabetes is linked to a 112 percent higher risk of death for women with ovarian cancer. The research also showed that women with a specific type of ovarian cancer actually seemed to benefit from having a high blood pressure (hypertension) diagnosis. "This is a coincidental and unintended consequence of hypertension and its treatment," said study co-lead author Kirsten Moysich. She's a professor of oncology at Roswell Park Cancer Institute in Buffalo, N.Y. "But it's a silver lining to a serious but largely manageable medical condition that has reached epidemic prevalence in the U.S. and many other countries worldwide," Moysich said in an institute news release. The researchers reviewed data from 15 studies of ... Read more

Related support groups: High Blood Pressure, Hypertension, Ovarian Cancer, Hypertensive Heart Disease

Sexual Abuse May Cause Early Puberty in Girls: Study

Posted 31 Mar 2017 by Drugs.com

FRIDAY, March 31, 2017 – It's common for parents to worry that their kids are growing up too fast. But in certain cases, early puberty in girls may be linked to sexual abuse, a small study suggests. Pennsylvania State University researchers examined data from 84 girls with a history of sexual abuse and 89 girls with no history of abuse. Those who were abused entered puberty eight to 12 months earlier than those who weren't abused, the investigators found. "Though a year's difference may seem trivial in the grand scheme of a life, this accelerated maturation has been linked to concerning consequences, including behavioral and mental health problems, and reproductive cancers," said study author Jennie Noll. She is director of the Child Maltreatment Solutions Network at Penn State. Typically, children's physical and mental development occur in tandem. "High-stress situations, such as ... Read more

Related support groups: Post Traumatic Stress Disorder, Breast Cancer, Ovarian Cancer, Precocious Puberty, Sexual Deviations or Disorders

Survival Continues to Improve for Most Cancers

Posted 31 Mar 2017 by Drugs.com

FRIDAY, March 31, 2017 – Overall cancer death rates in the United States continue to fall, but racial gaps persist, a new report says. Death rates fell between 2010 and 2014 for 11 of the 16 most common cancers in men and for 13 of the most common types in women, including lung, colon, prostate and breast cancers. However, death rates rose for cancers of the liver, pancreas and brain in men and for the liver and uterus in women. And improvements in cancer survival weren't equal for all Americans. "While this report found that five-year survival for most types of cancer improved among both blacks and whites over the past several decades, racial disparities for many common cancers have persisted, and they may have increased for prostate cancer and female breast cancer," said Dr. Lynne Penberthy. She's associate director of the U.S. National Cancer Institute's Surveillance Research ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Osteosarcoma, Skin Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Small Cell Lung Cancer, Bladder Cancer, Breast Cancer - Adjuvant, Cervical Cancer, Melanoma - Metastatic

Many Women Who Get Breast Cancer Gene Test Don't Need It

Posted 28 Mar 2017 by Drugs.com

TUESDAY, March 28, 2017 – An increasing number of American women who don't have breast or ovarian cancer are being tested for BRCA and BRCA2 gene mutations associated with those diseases, a new study shows. Mutations in the BRCA1 and BRCA2 genes significantly increase a woman's risk of breast cancer. These mutations are linked to 5 percent to 10 percent of all breast cancer and about 15 percent of ovarian cancers, the U.S. National Cancer Institute says. The new study found that more than 60 percent of BRCA tests are done on women without breast or ovarian cancer. In 2004, that number was just 24 percent. This increase is likely due to increased marketing of BRCA testing. This may lead women at low risk for BRCA mutations to self-refer for testing, the researchers said. While the number of low-risk women being tested has increased, BRCA testing is being underused by at-risk women, the ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Ovarian Cancer, Breast Cancer, Prevention, Diagnosis and Investigation

Zejula Approved for Certain Female Cancers

Posted 28 Mar 2017 by Drugs.com

TUESDAY, March 28, 2017 – Zejula (niraparib) has been approved by the U.S. Food and Drug Administration to treat adult women with recurring cancers of the ovaries, fallopian tubes or abdominal wall (peritoneum) whose tumors have shrunk in response to platinum-based chemotherapy. Citing the National Cancer Institute, the FDA said in a news release that more than 22,000 women are expected to be diagnosed with these cancers this year, and more than 14,000 will die of these diseases. Zejula is designed to block an enzyme involved in repairing damaged DNA. The thought is that by blocking this enzyme, cancer cells would die and slow down or stop tumor growth, the FDA said. The drug was evaluated in clinical studies involving 553 people with any of these recurring cancers who had had their tumors shrunk by at least two doses of platinum-based chemotherapy. The average progression-free ... Read more

Related support groups: Cancer, Ovarian Cancer, Zejula, Solid Tumors, Peritoneal Cancer, Niraparib

Tesaro Announces FDA Approval of Zejula (niraparib) for Women with Recurrent Ovarian Cancer

Posted 27 Mar 2017 by Drugs.com

WALTHAM, MA, March 27, 2017 – Tesaro, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib), an oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor, for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response (CR or PR) to platinum-based chemotherapy. Zejula is the first PARP inhibitor to be approved by the FDA that does not require BRCA mutation or other biomarker testing. Tesaro anticipates launching Zejula in the United States in late April. Zejula is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival (PFS) in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a r ... Read more

Related support groups: Cancer, Ovarian Cancer, Zejula, Peritoneal Cancer, Fallopian Tube Cancer, Niraparib

Another Study Ties Obesity to Certain Cancers

Posted 1 Mar 2017 by Drugs.com

WEDNESDAY, March 1, 2017 – Carrying extra weight increases the risk of a number of cancers, a new review reports. Additional pounds appear to particularly influence the risk of cancers related to the digestive organs or those driven by hormonal abnormalities, according to the review's European authors. The evidence is so strong at this point that important organizations such as the International Agency for Research on Cancer describe "excess body weight as an important cause of cancers," said Susan Gapstur. She's vice president of epidemiology at the American Cancer Society. The new evidence review was led by Maria Kyrgiou, of Imperial College London's Department of Surgery and Cancer. The review found that a jump in a person's body mass index (BMI) of 5 was associated with a higher cancer risk in the esophagus, bone marrow, biliary tract system, pancreas and kidneys. BMI is a rough ... Read more

Related support groups: Obesity, Cancer, Weight Loss, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Stomach Cancer, Gastric Cancer, Wilms' Tumor, Solid Tumors, Giant Cell Tumor of Bone, Neoplasm of Bone, Insulinoma, Peritoneal Cancer

Cancer Survivors Gain From Web-Based Health Care

Posted 10 Feb 2017 by Drugs.com

FRIDAY, Feb. 10, 2017 – Online- and phone-based health care offers a number of benefits for cancer survivors, British researchers report. The new study looked at previous research on cancer survivors' experiences with online and phone health contacts – what the researchers call telehealth. The review found that patients liked the flexibility and convenience of this method of staying in touch with their care providers because they could do so in a familiar, comfortable setting and with minimum disruption to their lives. The perceived anonymity of telehealth reduced patients' sense of vulnerability and some said they were more comfortable raising concerns in this setting than in face-to-face appointments. Negative aspects of telehealth mentioned by patients included not being able to meet their health care providers in person, while other patients said they couldn't use the service due ... Read more

Related support groups: Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Skin Cancer, Ovarian Cancer, Small Cell Lung Cancer, Bladder Cancer, Cervical Cancer, Stomach Cancer, Head and Neck Cancer, Breast Cancer, Prevention, Testicular Cancer, Breast Cancer - Palliative, Zollinger-Ellison Syndrome, Wilms' Tumor, Solid Tumors

Too Few High-Risk Women Tested for Breast Cancer Gene: Survey

Posted 7 Feb 2017 by Drugs.com

TUESDAY, Feb. 7, 2017 – Though testing for two genes that raise breast cancer risk has been around for decades, a new survey finds many high-risk women don't get the test, often because they aren't told to by their doctors. Among women with the highest risk, about eight of 10 said they wanted testing for the BRCA1 and BRCA2 mutations. But, "only about half of them actually got the testing they should get," said study author Dr. Allison Kurian, from Stanford University's School of Medicine. "Genetic cancer testing is not well matched to the medical needs of the patient, to a woman's risk of having a mutation," said Kurian, an associate professor of medicine and of health research and policy. Why the gap? About 56 percent of the high-risk women who were not tested said their doctors did not recommend it, the survey found. In addition to the test itself, genetic counseling can help ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Ovarian Cancer, Breast Cancer, Prevention, Breast Cancer - Palliative, Diagnosis and Investigation, Osteolytic Bone Metastases of Breast Cancer

Know the Risks, Warning Signs of Ovarian Cancer

Posted 19 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 18, 2017 – Women need to be aware their risk for ovarian cancer increases with age. Half of all cases affect women age 63 or older, according to specialists at Fox Chase Cancer Center in Philadelphia. However, the center reminds all women to be aware of other risk factors for the disease, as well as common ovarian cancer warning signs, such as: Belly bloating or swelling, Lower belly pain, Back pain, Trouble eating or feeling full quickly, Unexplained weight loss, Pain during sex, Menstrual changes, A change in bathroom habits, such as constipation, diarrhea, or having to urinate very badly or very often. "While these symptoms are common and may be caused by something other than ovarian cancer, I advise women to take them seriously," said Dr. Christina Chu, a Fox Chase gynecologic oncologist. "A woman knows what is normal for her own body. If her symptoms don't seem ... Read more

Related support groups: Birth Control, Contraception, Plan B, Cancer, Emergency Contraception, Mirena, Nexplanon, Depo-Provera, NuvaRing, Provera, Sprintec, Implanon, Urinary Tract Infection, Ortho Tri-Cyclen, Tri-Sprintec, Microgestin Fe 1/20, Yasmin, Loestrin 24 Fe, Plan B One-Step, Ortho Evra

FDA Grants Accelerated Approval to Rubraca (rucaparib) for Advanced Ovarian Cancer

Posted 20 Dec 2016 by Drugs.com

December 19, 2016 – The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test. “Today’s approval is another example of the trend we are seeing in developing targeted agents to treat cancers caused by specific mutations in a patient’s genes,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and acting director of the FDA’s Oncology Center of Excellence. “Women with these gene abnormalities who have tried at least two chemotherapy treatments for their ovarian cancer now have a ... Read more

Related support groups: Ovarian Cancer, Rubraca, Rucaparib

Ovarian Cancer Drug Given Fast-Track Approval

Posted 19 Dec 2016 by Drugs.com

MONDAY, Dec. 19, 2016 – The anti-cancer drug Rubraca (rucaparib) has been granted accelerated approval by the U.S. Food and Drug Administration to treat advanced ovarian cancer. The approval is limited to cases where the cancer is caused by specific gene mutations known as "deleterious BRCA." BRCA genes normally repair damaged DNA and are designed to prevent tumor growth, the agency said Monday in a news release. But mutations in these genes could lead to cancer. Rubraca is designed to inhibit a certain enzyme that's produced by a damaged BRCA gene. More than 22,000 women are projected to be diagnosed with ovarian cancer this year, and more than 14,000 are projected to die from the disease, according to U.S. National Cancer Institute estimates cited by the FDA. The FDA simultaneously approved the FoundationFocus CDxBRCA diagnostic screen. This screen detects the presence of deleterious ... Read more

Related support groups: Ovarian Cancer, Acute Myeloid Leukemia

FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer

Posted 7 Dec 2016 by Drugs.com

South San Francisco, CA – December 6, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Women are said to have a ‘platinum-sensitive’ form of the disease if a relapse occurs six months or longer following the last treatment with a platinum-based chemotherapy. “With today’s approval of Avastin plus chemotherapy, women in the U.S. with recurrent, platinum-sensitive ovarian cancer now have a treatment option that showed a survival difference of more than five months compared to chemotherapy al ... Read more

Related support groups: Avastin, Ovarian Cancer, Bevacizumab, Fallopian Tube Cancer, Peritoneal Cancer

Worldwide Cancer Rates Up More Than One-Third in Past Decade: Report

Posted 4 Dec 2016 by Drugs.com

SATURDAY, Dec. 3, 2016 – Cancer cases rose 33 percent worldwide in the past 10 years, a new study shows. In 2015, there were 17.5 million diagnoses and 8.7 million deaths in the world from the disease, the researchers found. The rise in cancer cases was mainly due to population aging and growth, along with changes in age-specific cancer rates, according to the Global Burden of Disease Cancer Collaboration study. The lifetime risk of developing cancer was one in three for men and one in four for women, the researchers said. Prostate cancer was the most common type of cancer in men (1.6 million cases), and tracheal, bronchus and lung cancer was the leading cause of cancer death in men. Breast cancer was the most common cancer for women (2.4 million cases), and the leading cause of cancer death in women. The most common cancers in children were leukemia, other neoplasms, non-Hodgkin ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma, Melanoma, Skin Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Cancer, Testicular Cancer, Salivary Gland Cancer, Solid Tumors

'Magic Mushroom' Chemical Eases Cancer Patients' Despair

Posted 1 Dec 2016 by Drugs.com

THURSDAY, Dec. 1, 2016 – Cancer often leaves patients feeling that life has no meaning, a state of mind that psychiatrists call "existential distress." But two new, small studies suggest that an ingredient found in hallucinogenic "magic" mushrooms can dramatically reverse this feeling. A single dose of the man-made drug psilocybin quickly lifted spirits for most cancer patients, and the effect lasted as long as six months for many, the researchers reported. One patient described her experience as "life-changing." "In 2010, I was diagnosed with ovarian cancer," Dinah Bazer, who took part in one of the studies, said during a Wednesday media conference. "Following successful surgery and chemotherapy, I was totally consumed with anxiety and fear of recurrence for over two years," she said. "It was running my life and ruining my life." After taking psilocybin, "I was bathed in God's love, ... Read more

Related support groups: Cancer, Substance Abuse, Ovarian Cancer, Toxic Reactions Incl Drug and Substance Abuse

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Cancer

Related Drug Support Groups

methotrexate, Avastin, Taxol, carboplatin, cisplatin, Cytoxan, cyclophosphamide, paclitaxel, Gemzar, view more... gemcitabine, doxorubicin, Adriamycin, topotecan, Hycamtin, etoposide, bevacizumab, amifostine, Zejula, Platinol, Alkeran, Lynparza, Rubraca, Doxil, olaparib, Hexalen, thiotepa, melphalan, Tepadina, Adriamycin PFS, Cytoxan Lyophilized, Thioplex, Platinol-AQ, Carboplatin Novaplus, Adriamycin RDF, Neosar, niraparib, Ethyol, rucaparib, doxorubicin liposomal, dactinomycin, Paraplatin, altretamine, Toposar, Etopophos, VePesid, Cosmegen, Onxol